Therapy News and Research

RSS

Need for better understanding of appropriate treatment choices for children with insomnia: Study

A new survey of child psychiatrists indicates that insomnia is a major problem among children in mental health treatment and at least a quarter of these patients are given sleep medication. The results of the survey, conducted by Judith Owens, MD, a sleep expert with Hasbro Children's Hospital, and colleagues, suggests that management of insomnia in this population is a common practice, although the clinical approach varies widely. The study is published in the August 2010 edition of Sleep Medicine.

27 Jul 2010

Report finds geographic variation in the use of carotid endarterectomy, carotid stenting

Medicare beneficiaries in some parts of the United States appear more likely to receive carotid endarterectomy, a surgical procedure to clear blockages in the artery supplying blood to the head, whereas those in other regions more often receive stents for the same condition, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Jul 2010

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. A team of researchers, led by Alberto Bardelli, at the University of Turin Medical School, Italy, has now identified a way to help predict which patients will respond to such drugs.

27 Jul 2010

NCCN enters into collaboration to introduce Proventys CDS Oncology system

The National Comprehensive Cancer Network and Proventys, a leader in advanced decision support technologies, have entered into an exclusive collaboration to introduce the Proventys CDS Oncology system, a first-of-its-kind Web platform that arms oncologists with expert recommendations and evidence facilitating the delivery of high-quality, individualized patient care.

27 Jul 2010

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

For the third time in four months, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a research grant aimed at helping people infected with multidrug-resistant tuberculosis. Taken together, all three NIH grants total $8.57 million.

27 Jul 2010

Iverson Genetic Diagnostics receives CMS approval for Warfarin clinical study

Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.

27 Jul 2010

Braun Corporation presents key themes, recommendations discussed at symposium for the disabled

The Braun Corporation, the world's largest manufacturer of wheelchair-accessible vans, ramps and wheelchair lifts, today published key insights from a symposium hosted recently in Washington, D.C. titled "ADA 20/20: Looking Back, Looking Forward on Mobility." In anticipation of the 20th anniversary of the Americans with Disabilities Act, the panel of key thought leaders from government, medicine, academia and business exchanged insights on current thinking around future mobility needs for Americans with disabilities.

27 Jul 2010

Study on treatment needs of prostate cancer patients with low level PSA

Controversy has long existed over the benefit of the prostate specific antigen (PSA) test used to screen for the presence of prostate cancer, and there has been little study to document the risk profile of men who have a PSA level at or below what is considered 'normal.' New research published in the latest edition of Archives of Internal Medicine (Vol. 170, No. 14) by a team of investigators at The Cancer Institute of New Jersey (CINJ), further explores this population. The findings show that most men with prostate cancer who tested below the normal PSA level and had low-risk disease nevertheless underwent aggressive treatment. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

27 Jul 2010

Federal prosecutors drop long-standing fraud charges against doctor from the Philippines

"Federal prosecutors have dropped charges against a doctor from the Philippines who went into hiding after being accused of scamming a military health program out of more than $1 million in the 1990s," The Associated Press reports.

27 Jul 2010

Childhood cancer survival associated with high risk of abnormal cardiac function

Childhood cancer survival is associated with increased risk of long-term abnormalities in cardiac function, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Jul 2010

Teva second-quarter net sales increase 12% to $3.8 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2010.

27 Jul 2010

Study on interactions between new antitubercular drug candidates SQ109 and TMC207

Sequella, Inc., a clinical-stage biopharmaceutical company developing drugs for treatment of life-threatening infectious diseases, announced today the publication of studies in the scientific journal Antimicrobial Agents and Chemotherapy on synergy between SQ109, its lead drug candidate for the treatment of TB, and TMC207, Tibotec lead TB drug candidate:

27 Jul 2010

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an additional $195,000 for the second year starting August 1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project. The grant will be administered by the National Institute of Neurological Disorders and Stroke.

27 Jul 2010

Consumers struggle to sort out many stem cell claims

NPR reports on the confusion among consumers about stem cell therapy. It's easy to find on websites and other advertisements claims of cures for practically every medical condition, but traditional American medical doctors say that so far stem cell therapy has been proven to work in only a few blood disorders.

27 Jul 2010

Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor

Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CoaguChek® XS Pro system, a new point-of-care anticoagulation monitor with a built-in bar code reader that can automatically scan and capture operator and patient identification information.

From Roche Sequencing and Life Science 27 Jul 2010

QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy

QRxPharmareported today positive outcomes of its European Scientific Advice meetings on the development and registration of MoxDuo IR, an immediate release Dual-Opioid™ pain therapy. The Company is currently completing pivotal Phase 3 trials required for filing a New Drug Application (NDA) for MoxDuo IR with the United States Food and Drug Administration (FDA).

26 Jul 2010

Adventist Hinsdale Hospital, Marianjoy announce partnership

Patients with acute physical rehabilitation needs now can undergo inpatient treatment close to home thanks to a new partnership between Adventist Hinsdale Hospital and Marianjoy Rehabilitation Hospital. Announced today, the cooperative effort unites two organizations with similar holistic approaches to rehabilitative patient care for a variety of conditions in multiple settings.

26 Jul 2010

CPC partners with CU School of Medicine on stem cell research

A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.

26 Jul 2010

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a Phase 1/2 clinical trial of CF102 in the treatment of patients with advanced HCC.

26 Jul 2010

QPS acquires Xendo Drug Development

QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development BV (XDD), headquartered in Groningen, The Netherlands. XDD, a European contract research organization (CRO), will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC.

26 Jul 2010

Therapy News and Research

Need for better understanding of appropriate treatment choices for children with insomnia: Study

Report finds geographic variation in the use of carotid endarterectomy, carotid stenting

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

NCCN enters into collaboration to introduce Proventys CDS Oncology system

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

Iverson Genetic Diagnostics receives CMS approval for Warfarin clinical study

Braun Corporation presents key themes, recommendations discussed at symposium for the disabled

Study on treatment needs of prostate cancer patients with low level PSA

Federal prosecutors drop long-standing fraud charges against doctor from the Philippines

Childhood cancer survival associated with high risk of abnormal cardiac function

Teva second-quarter net sales increase 12% to $3.8 billion

Study on interactions between new antitubercular drug candidates SQ109 and TMC207

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Consumers struggle to sort out many stem cell claims

Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor

QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy

Adventist Hinsdale Hospital, Marianjoy announce partnership

CPC partners with CU School of Medicine on stem cell research

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

QPS acquires Xendo Drug Development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News